Physician profile
Jong Wook An
NPI 1043419096
$5,989.37
in general payments reported to CMS, 2019-2025
55 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.91 · 2021: $51.51 · 2022: $931 · 2023: $2,612 · 2024: $2,049 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,641 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,641.44 |
| Education | $352.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $600.47 | 2022-2024 | |
| Pfizer INC. | $492.25 | 2022-2025 | |
| Astellas Pharma US INC | $458.77 | 2023-2024 | Padcev, Xtandi, Xospata |
| Astrazeneca Pharmaceuticals Lp | $413.51 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Incyte Corporation | $256.07 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Dendreon Pharmaceuticals LLC | $255.80 | 2022-2025 | Provenge |
| Servier Pharmaceuticals LLC | $216.62 | 2022-2024 | |
| Daiichi Sankyo INC. | $216.16 | 2023-2024 | Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $209.51 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $203.26 | 2022-2024 | |
| Genzyme Corporation | $190.63 | 2022-2024 | |
| Eisai INC. | $168.08 | 2022-2024 | |
| Lilly USA, LLC | $147.90 | 2022 | |
| Janssen Biotech, INC. | $140.54 | 2023-2024 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $119.21 | 2022-2024 | Keytruda, Welireg, Lynparza |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $114.96 | 2023-2024 | Venclexta, Polivy, Lunsumio |
| Adaptive Biotechnologies Corporation | $112.17 | 2022-2024 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $103.10 | 2023-2024 | Onivyde, Somatuline Depot, Tazverik |
| Regeneron Healthcare Solutions, INC. | $95.24 | 2023 | Libtayo |
| Abbvie INC. | $86.22 | 2023-2024 | Venclexta |
| Mirati Therapeutics, INC. | $81.61 | 2023 | Krazati |
| Seagen INC. | $80.00 | 2022-2023 | Padcev, Adcetris |
| Taiho Oncology, INC. | $71.72 | 2023-2024 | |
| Pharmaessentia USA Corporation | $70.16 | 2022-2024 | Besremi |
| Beigene USA, INC. | $66.45 | 2023-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $66.28 | 2022-2024 | Xpovio |
| G1 Therapeutics, INC. | $65.20 | 2022-2023 | Cosela |
| Exelixis INC. | $64.81 | 2023 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $64.00 | 2022-2024 | Alunbrig, Fruzaqla |
| Array Biopharma INC | $62.51 | 2022-2023 | Lorbrena, Braftovi, Mektovi |
| E.R. Squibb & Sons, L.L.C. | $57.25 | 2023 | Opdivo |
| Octapharma USA, INC. | $54.54 | 2024-2025 | Octagam Immune Globulin (Human) |
| Amgen INC. | $52.74 | 2022-2023 | Lumakras |
| Celgene Corporation | $48.33 | 2022-2023 | Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $47.99 | 2022 | |
| Adc Therapeutics America, INC. | $41.70 | 2022-2024 | |
| Spectrum Pharmaceuticals INC. | $41.10 | 2024 | Rolvedon |
| Puma Biotechnology, INC. | $33.56 | 2022-2023 | |
| Sirtex Medical INC | $29.64 | 2024 | Sir-Spheres Microspheres |
| Immunogen, INC. | $27.65 | 2023 | Elahere |
| Tempus Ai, INC | $27.34 | 2024 | Xt Cdx |
| Kite Pharma, INC. | $24.54 | 2023 | |
| Cti Biopharma Corp. | $21.04 | 2022 | |
| Emd Serono, INC. | $20.79 | 2024 | |
| Jazz Pharmaceuticals INC. | $20.61 | 2022 | |
| Genmab U.S., INC. | $18.39 | 2023 | Epkinly |
| Tersera Therapeutics LLC | $17.23 | 2022 | |
| Acrotech Biopharma INC. | $16.19 | 2024 | Beleodaq |
| Alexion Pharmaceuticals, INC. | $15.14 | 2024 | Ultomiris |
| Organon LLC | $14.97 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.73 | 2024 | Givlaari |
| Pharming Healthcare, INC. | $14.31 | 2024 | Ruconest |
| Agios Pharmaceuticals, INC. | $14.28 | 2024 | Pyrukynd |
| Novocure INC. | $12.46 | 2021 | |
| Heron Therapeutics, INC. | $9.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong An listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.